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Introduction/objective: Ventilator-associated pneumonia (VAP) is the hospital-acquired infection 
with the greatest impact on patient outcomes and health care costs. Endogenous colonization by 
aerobic gram-negative bacteria such as Pseudomonas aeruginosa play a pivotal role in the 
pathogenesis of VAP. The aim of this work was the characterisation of the resistome and virulome 
of a collection of P. aeruginosa isolates from patients with VAP collected during a multicentre 
study. 
Material and methods: We analysed 38 isolates (1 per patient) of P. aeruginosa from patients with 
VAP. Minimum inhibitory concentrations (MICs) of 16 different antibiotics were determined by 
broth microdilution according to the Clinical and Laboratory Standard Institute (CLSI) and the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints. 
The complete genomes of all the isolates were sequenced using the MiSeq platform (Illumina) to 
determine their clonal relationship, as well as the presence of antibiotic resistance and virulence 
related genes. 
Results: According to antibiotic resistance, 10.5% (n=4) of the isolates were multi-susceptible 
and 23.7% (n=9) moderately resistant, while 21.1% (n=8) were multidrug-resistant and 44.7% 
(n=17) were extensively resistant. Forty-five genes related with antibiotic resistance were 
detected: blaGES-7 and blaVIM (1,2 and 20) were observed on extensively resistant isolates. 
According to the results obtained from the Virulence finder database (VFDB), the virulome of 
the whole population was made up of 294 genes, among which the most significant were the 
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Pneumonia is defined as an inflammatory condition of the lungs, caused mostly by bacteria or 
virus. Affected people usually report cough, chest pain, fever, and difficulty for breathing. 
Ventilator-Associated Pneumonia (VAP) is defined as a pneumonia that appears 48h+ after the 
initiation of mechanical ventilation or endotracheal intubation (Davis; 2006). It is the most 
acquired infection in the intensive-care-unit with an incidence sometimes greater than 50% 
(Koenig & Truwit; 2006). The wall of the tubes inserted into the patient body allow for a great 
development of different pathogens, mostly bacteria, that will continue their way up to the lungs 
of the individual, causing this infection. 
 
 
Figure 1: Source of VAP. pathogens which lead to the infection. (a) & (b) represent endogenous sources 
(oropharyngeal and gastric colonization), (c), (d) & (e) exogenous ones (contaminated air, instruments, or other 




There are many risk factors related to this condition, being burnt patients the most problematic 
one, as they tend to get infected more consistently and usually have worse prognosis. Age, 
immunosuppression, organ failure, and post-traumatic situations should also be considered. 
 
Table 1: Complete list of risk factors on VAP. Divided on host or intervention factors. (Joseph et al; 2010) 
 
 
The most common pathogens causing VAP are Pseudomonas species, Acinetobacter species, and 
Gram-negative bacilli expressing Extended Spectrum β-lactamases (ESBL) and AmpC β-
lactamases. Due to these characteristics these bacteria are known as multridug-resistant (MDR) 
pathogens (Trouillet et al; 1998). Prior hospitalization or antibiotic treatment within the past 90 
days predisposes to colonization and infection by MDR pathogens. Usually VAP is caused by 
more than 1 microorganism, between 30 and 70% of the cases are polymicrobial (Torres & Carlet; 
2001). 
In order to understand how to better treat this kind of infections, we must know first who we are 
fighting against. The complex resistance mechanisms and virulence factors seen on Pseudomonas 









Pseudomonas aeruginosa is a Gram-negative rod-shaped gamma-proteobacterium. It can be 
found in many ecological niches due to its metabolic versatility. It is capable of colonizing 
different living beings such as plants, animals, and humans. It is associated with a wide range of 
acute and chronic infections such as cystic fibrosis (CF), VAP, urinary tract infections, otitis, burn 
injuries and bacteremia. 
P. aeruginosa is one of the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumannii, P. aeruginosa, and Enterobacter species), 
which confirms its impact on hospital infections and how capable it is to “escape” the activity of 
a wide range of antibiotics. This species has also been included in the World Health Organization 
(WHO) list of pathogens under the “critical” category for which new antibiotics research is 
urgently required. The United States Center for Disease Control and prevention (CDC) flagged 
P. aeruginosa as a serious threat. 
 
 
Figure 2: P. aeruginosa is considered one of the most important bacterial pathogens affecting human populations 
according to a big number of organizations like WHO or CDC. (Botelho et al; 2019) 
 
Metabolic versatility, a huge number of virulence factors, the formation of biofilm, and its 
antibiotic resistance (AR) are the pillars of P. aeruginosa pathogenicity. All of them will be 
explored in this work. 
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1.3-Antibiotic resistance on P. aeruginosa  
Antibiotics can be both a really powerful weapon against pathogens and the last ingredient needed 
to create a pan-resistant bacteria depending on the proper application. Its inappropriate use has 
promoted the appearance of AR in most bacteria. The WHO made a report with data from more 
than 100 countries showing that AR is present everywhere (WHO; 2015). It also lists AR as one 
of the top risks the world will face in the near future. Around 700.000 people die every year 
because of AR infections worldwide (O´Neill; 2016). According to the latest European Centre for 
Disease Control (ECDC) AR report, 12.9% of P. aeruginosa isolates have resistance to three or 
more antibiotic groups (ECDC; 2017). Eight families of antibiotics are generally used for 
treatment of infections provoked by P. aeruginosa: 
 
Table 2: Different antibiotic families, their action mechanism and resistance mechanisms developed by P. aeruginosa 





Pseudomonas aeruginosa shows resistance to a wide number of antibiotics, including 
aminoglycosides, quinolones, and β-lactams (Hancock and Speert; 2000). In order to classify the 
different mechanisms that P. aeruginosa has developed to fight antibiotic attacks we will use 
three different categories: 
 
Intrinsic antibiotic resistance 
The intrinsic antibiotic resistance of a bacterial species can be defined as the inherent ability to 
block partially or completely the efficacy of a given antibiotic by structural or functional 
characteristics (Blair et al; 2015). P. aeruginosa has three mechanisms which provide great 
resistance to most antibiotics intrinsically: 
 Outer membrane permeability: Most antibiotics need to penetrate the cell 
membrane in order to work (Aminoglycoside by binding to 30S subunits (Mingeot-
Leclercq et al; 1999), quinolones by inhibiting DNA gyrase and topoisomerase (Aldred 
et al; 2014), β-lactams by blocking cell wall biosynthesis (Poole; 2004), Polymyxins by 
binding to lipopolysaccharides (LPS) of the outer membrane (Zavascki et al; 2007)). P. 
aeruginosa outer membrane is an asymmetric bilayer of phospholipid and LPS, with 
embedded β-barrel protein channels called porins (Delcour; 2009). Porins can be divided 
into four classes, depending on the substrates they work with. Regarding the topic of this 
work the most important ones are efflux porins, which are key components of efflux 
pumps, in P. aeruginosa, efflux porins include the following main proteins: OprM, OprN, 
and OprJ (Hancock & Brinkman; 2002). Also, P. aeruginosa membrane has an extremely 
low permeability, around 100-fold lower than E. coli K12 (Yoshimura et al; 1982). OprF 
protein is the main porin of P. aeruginosa responsible for non-specific uptake of ions and 
saccharides and it has a low efficiency on antibiotic uptake, this is caused by the fact that 
this protein has 2 conformational states, being the closed one the most common (about 
95%) allowing only for a 5% of open channels (Bellido et al; 1992). 
 
 Efflux systems: Out of the five families of efflux pumps; Resistance-Nodulation-
Division (RND) plays a key role in P. aeruginosa antibiotic resistance and thus is the one 
we are going to focus on in this work. They are made of 3 components: Cytoplasmic 
membrane transporters, periplasmic linker proteins and outer membrane porin channel 
proteins. The cytoplasmic and periplasmic components of this pumps are named 
multidrug efflux (Mex) along with a letter, and the porin is named Opr along with a letter 
as we have already seen above. Out of the 12 pumps among this family, 4 are capable of 
pumping out the different drugs (Dreier & Ruggerone; 2015). Overexpression of this 
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RND family efflux pumps has been found in some clinical strains of P. aeruginosa, 
contributing to the development of multidrug-resistance (Cabot et al; 2011). 
 
Table 3: Major RND multridug efflux pumps of P. aeruginosa and their substrates. (El Zowalaty et al; 2015) 
 
 
 Antibiotic-inactivating enzymes: One of the major mechanisms of intrinsic 
resistance seen in bacteria. Most antibiotics have chemical bonds susceptible to 
hydrolysis by enzymes commonly found on P. aeruginosa like β-lactamases (Wolter & 
Lister; 2013). ampC is the gene encoding this enzyme, it will break the amide bond of the 
β-lactam leading to its inactivation. β-lactamases can be classified into four groups A, B, 
C, and D based on their amino acid sequences. Some strains of P. aeruginosa have been 
found to produce ESBLs conferring great resistance to most β-lactam antibiotics, 
including penicillins, cephalosporins and aztreonam (Paterson & Bonomo; 2015). 
Antibiotic-inactivating enzymes are probably the most important method of resistance 




Figure 3: Intrinsic resistance mechanisms on P. aeruginosa. Restricted outer membrane permeability, pump efflux 
systems, and inactivating enzymes work all together to avoid being affected by the drugs. (Pang et al; 2019) 
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Acquired antibiotic resistance 
There are two mechanisms by which P. aeruginosa can gain this kind of resistance: Mutational 
changes and horizontal gene transfer. Both methods contribute to the already high intrinsic 
antibiotic resistance of this bacteria increasing the difficulty eradicating the microorganism and 
allowing for more persistent infections (Henrichfreise et al; 2007): 
 Resistance by mutation: Mutational changes allow for reduced antibiotic penetration, 
modification of targets and overexpression of efflux pumps or inactivating enzymes. For 
example, mutations on OprD allow P. aeruginosa to resist extremely well against 
carbapenems by modifying its binding site on the porins (Fang et al; 2014) also the 
overexpression of MexAB-OprM enhances the resistance against β-lactams and 
fluoroquinolones by increasing the production of RND efflux pumps (Tian et al; 2016). 
Detailed mechanism on Figure 4. 
 
 Acquisition of resistance genes: These genes can be carried on plasmids, 
transposons, integrons, prophages and the chromosomes. They can be exchanged with 
other species of bacteria and not only P. aeruginosa (Breidenstein et al; 2011). The most 
interesting example is probably metallo-beta-lactamases (MBLs) a group of enzymes 
(class B β-lactamases) that hydrolyze most β-lactam-based antibiotics. These MBLs, 
which are not originally found on P. aeruginosa have been detected in integrons as well 
as plasmids of this species (Cavalcanti; 2015). Mechanisms by which this process takes 
place can be seen on Figure 5. 
 
 
Figure 4: Scheme of the RDN family efflux pump seen on P. aeruginosa. Antibiotics are sent off the cell with the 




Figure 5: Mechanisms of horizontal gene transfer between bacteria. A) Conjugation involves direct contact between 
two individuals for DNA transfer. B) Transduction requires a bacteriophage to transfer the DNA. C) Transformation 
requires the release of DNA fragments from the donor cell that are later picked up from the medium by the recipient 
cell. (Pang et al; 2019) 
 
 
Figure 6: Different carbapenemases found on P. aeruginosa isolates from NCBI database. Each colour represents a 
family. In Spain we can find 4 different families: VIM, DIM-1 GES, and IMP (from more common to scarcer). (Botelho 
et al; 2019) 
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Adaptive antibiotic resistance 
It is defined as the ability to resist an antibiotic attack by the alteration of gene and/or protein 
expression due to an environmental stimulus. It must be reversible in order to be considered as an 
adaptive response (Sandoval-Motta & Aldana; 2016). In P. aeruginosa, 2 strategies have been 
widely characterized: 
 Biofilm-mediated resistance: A biofilm is an aggregate of microorganisms (mostly 
bacteria) on top of a living or non-living surface. Biofilm is made of a matrix where cells 
are embedded, mostly made of extracellular polymeric substances (EPS) which includes 
exopolysaccharides, proteins, DNA fragments and other metabolites (Donlan; 2002). 
Biofilm protects bacteria from antibiotics by preventing its penetration and slowing down 
the metabolism or inducing stress responses of the cells inside of it. In P. aeruginosa, 
biofilm formation is multifactorial. Quorum sensing (Bacterial cells communicate 
through metabolites and react to cell density altering gene expression) as well as 
exopolysaccharides and cdi-GMP coordinate this process. Once the cells take part in the 
biofilm structure, they begin to change their physical and physiological shape (Drenkard; 
2003). Alginate production gets upregulated to create the matrix and flagellum gets 
downregulated as the cells will not move anymore. This makes it harder for the immune 
system to detect P. aeruginosa (Jyot et al; 2007), (Figure 7). 
 
 
Figure 7: Scheme of the basic P. aeruginosa biofilm formation process. Motile cells attach themselves to a surface in 
a reversible way, after that they get attached completely through adhesins to form a monolayer. These cells will 
produce the matrix and multiply creating complex 3D structures known as mature biofilm. Finally, some cells leave 




 Persister cells in antibiotic resistance: These cells are phenotypical variants without 
any genetical antibiotic resistance but with high tolerance due to its almost inexistent 
metabolism. Around 1% of the P. aeruginosa individuals inside a biofilm are persister 
cells (Wood et al; 2013). While most of the cells can be killed with antibiotics, this special 
kind can resist the attack by shutting down the synthesis of the antibiotic targets and 
entering dormancy (Van den Bergh et al; 2017). Persister cells are not able to grow under 
presence of antibiotics but will resume its growth once the treatment is over, that is why 
it is believed that they are responsible for chronic infections (Maisonneuve & Gerdes; 




Figure 8: Comparison between resistant and persister cells. Top panel shows a bacterial population with resistant 
individual reacting to an antibiotic, only resistant cells will survive and thus replenish the population later on. Lower 
panel shows a bacterial population with persister cells, once the treatment has finished, they will multiply and 
colonize the environment again, but with bacteria that are not resistant to the antibiotic previously applied. (Fauvert 









1.4-Virulence factors on P. aeruginosa  
Several virulence factors can be found in different bacteria, these will facilitate adhesion and/or 
disrupt host cell signalling pathways. P. aeruginosa is known of having a wide number of them: 
LPS, Flagellum, Type IV Pili, Type I, II, III, V and VI Secretion Systems, Proteases, Alginate, 
Quorum Sensing and Biofilm formation being the most known (Rocha et al; 2019). The most 
important ones will be resumed in the following pages: 
 LPS: Consists of 3 parts: Lipid A, which is the hydrophobic portion that anchors the 
molecule in the outer membrane. The core, which is made mostly of hexoses and 
hexosamines and due to its negative charge provides membrane stability, and lastly, the 
O antigen, which is the long polysaccharide ranging from one to hundreds of sugars 
(Huszczynski et al; 2020). It is synthesized separately from the Lipid A-core and then 
attached to it. LPS is an inducer of the complement system thus producing different 
cascades of inflammation on the host (Schreiber et al; 1993). There are some strains that 
lack O antigen, which makes them less aggressive against the host as O antigen protects 
bacteria from phagocytosis and antibodies reaching the surface of the cell (Engels et al; 
1985). 
 
 Type I Secretion System: T1SS displays the typical ATP binding cassete-exporter 
secretion complex, capable of exporting proteins out of the cell. Little is known about the 
importance of this system on the virulence of P. aeruginosa, but an alkaline protease 
(AprA) uses this system to reach the environment (Guzzo et al; 1991). 
 
 Type II Secretion System: T2SS secretes a wide variety of toxins: LasA and LasB 
proteases, phospholipase H, lipolytic enzimes and the most important one in which we 
will focus: Exotoxin A. It is a protein of 638 amino acids coming from PE gene and 
divides in several structural and functional domains. Once it is secreted from the bacteria, 
Exotoxin A will bind to KDEL receptors of the Golgi apparatus of the host (Hessler & 
Kreitman; 1997), later, following two different pathways, the toxin will reach its 
objective: Endoplasmic Reticulum (ER). After reaching ER, the toxin activates a protein 
degradation route to be freed at the cytosol (Ogata et al; 1992). In the cytosol, the toxin 
binds to the ribosomes activating its enzymatic activity, producing the ADP-Ribosylation 





 Type III Secretion System: T3SS is made of thirty-six genes encoded in five operons 
clustered together in the P. aeruginosa chromosome. Another six different genes encode 
for the effector proteins and their chaperones. Only 4 effectors have been characterised 
on P. aeruginosa: ExoS, ExoU, ExoT, and ExoY. Nearly all strains have either the exoS 
or the exoU gene and both the exoT and the exoY. They will be briefly described now 
based on information from Table 4. 
 
Table 4: Characteristics of Pseudomonas aeruginosa T3SS efector proteins. (Hauser; 2009) 
 
 
1. ExoS: It is a bifunctional toxin that has both GTPase-activating protein (GAP) and 
ADP ribosyl trans-ferase (ADPRT) activity. The GAP domain targets Rho, Rac and 
cell division cycle 42 (CDC42) which are small GTPases related to the organization 
of the actin cytoskeleton in the host cell. ExoS inactivates all of them leading to the 
disruption of the cytoskeleton (Pederson et al; 1999) It has been suggested that this 
has a role in avoidance of phagocytosis. ADPRT domain has a binding site for a 
eukaryotic cofactor needed for ADPRT activity. This protects P. aeruginosa from 
attacking itself with such a potent weapon. Once active, ExoS has several adverse 
effects: Cell death, actin cytoskeleton disruption, and inhibition of DNA synthesis 
(Rocha et al; 2003). 
 
2. ExoT: It shares 76% amino acid identity with ExoS. It has the same GAP and 
ADPRT activity as ExoS. The enzymatic activities of this enzyme have been linked 
with delays in wound healing, which can allow P. aeruginosa to exploit breaches in 
mucosal barriers more strongly (Garrity-Ryan et al; 2004). 
 
3. ExoU: It is a potent phospholipase, capable of causing fast cell death. Like ExoS or 
ExoT it requires an eukaryotic cofactor in order to work. It has been found that it 
binds to Superoxide dismutase (SOD1), but its enzymatic activity is not needed for 
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ExoU to work (Sato et al; 2003). Cell death caused by this effector is produced by 
the breaking off the membrane which is consistent with necrosis (Finck-Barbançon 
et al; 1997). 
 
4. ExoY: It is considered as an adenylyl cyclase. It binds to ATP and also requires a 
host cell factor for full enzymatic activity. If injected on mammalian cells an 
elevation on cAMP is observed (Yahr et al; 1998). This effect disrupts the actin 
cytoskeleton while increasing endothelial permeability. This is yet to be observed on 
real situations and the importance of ExoY in infection remains unclear. 
 
 Type V Secretion System: T5SS works in a very similar way to T2SS, it is widespread 
on Gram negative bacteria and it can secret a wide number of proteins. Recently PlpD 
enzyme was described. This enzyme has great phospholipase activity allowing for the 
recognition of many phosphatydilinositols, key components of eukaryotic cell membrane 
thus allowing for an easier colonization (da Mata Madeira et al; 2016). 
 
 Type VI Secretion System: The latest secretion system described. Works like a needle, 
inyecting toxins inside the cells with whom it makes contact. It is believed that it helps 
during competition with other bacteria in the environment. It allows of a better 
internalization on epithelial cells. Its structure is very similar to the dynamic contractile 
tail of a phage (Figure 9). Different effectors can be found: Tse1 and 3 which acts by 
degrading peptidoglycan and thus dissolving other cells, Tse2 which targets bacterial 
cytoplasm inhibiting growth and PldA/B, lipases that degrade 
phosphatidylethanolamine and phosphatidylinositol respectively, In order to avoid being 
attacked by its own effectors, P. aeruginosa has antitoxins for each of this proteins (Chen 
et al; 2015). 
 
 Biofilm: It has already been briefly summarized under the Resistance methods of P. 
aeruginosa. Biofilm allows the survival of the cells inside of it because of its extracellular 
matrix, that does not let antibiotics pass through. Also, the conditions found inside the 
biofilm makes the perfect environment for the arise of persister cells, even more resistant 
to drugs due to its almost zero metabolism. P. aeruginosa is notorious for causing 
pneumonia on CF patients, biofilms settle in the mucus and induce inflammation by 
recruiting polymorphonuclear leukocytes (Murray et al; 2007). The chronic inflammatory 
response causes tissue damage and leads to lung failure (Tolker-Nielsen; 2014). It also 
allows for infections in the ears, prostate gland, wounds, and works together with T3SS 




Figure 9: Similarities between phage tails and T6SS complex. Most of the structural proteins found on this secretion 
system are believed to come from the bacteriophages. While phages contract to inject DNA, T6SS does it to inject 
certain toxins. (Ho et al; 2014) 
 
2.-Aims of the study 
The main goal of this study was to characterize the resistome and virulome of P. aeruginosa 




1. To study the in vitro activity of antimicrobials of clinical interest using a standardized 
method against an established collection of P. aeruginosa strains isolated from patients 
with VAP. 
  
2. To determine the clonal relationship between the different clinical isolates of P. 
aeruginosa by multilocus sequence typing. 
 
3. To Sequence the complete genomes of the P. aeruginosa isolates from patients with VAP 
in order to identify the presence of acquired antibiotic resistant genes such a as 






3.-Materials and Methods 
 
3.1-Bacterial Isolates, Medium and Culture Conditions 
Out of a 200+ collection of P. aeruginosa non duplicated isolates from patients with VAP 
collected from different hospitals across Spain, 38 were selected for analysis. Bacteria were 
routinely grown on Mueller-Hinton agar at 37ºC (typical human body temperature), which is 
suitable for P. aeruginosa growth and standardized for most testing procedures. Once an isolate 
was received, it was grown in a Mueller-Hinton agar petri dish to confirm its isolation and stored 
at -80ºC in glycerol until it was needed. 
 
3.2-Antibiotic Susceptibility Testing 
Minimum Inhibitory Concentration (MIC) of aztreonam (AZT), ceftazidime (CAZ), cefepime 
(FEP), imipenem (IMP), meropenem (MER), doripenem (DOR), piperacillin (PIP), piperacillin – 
tazobactam (TZP), gentamicin (GEN), tobramycin (TOB), amikacin (AK), levofloxacin (LEV), 
ciprofloxacin (CIP), colistin (COL), polymyxin B (PB) and fosfomycin (FOS) were determined 
by the broth microdilution method according with CLSI guidelines (CLSI, 2018), Table 2. 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints 
were followed when interpreting results (EUCAST; 2020).  
 
 
Figure 10: Example of a microdilution essay result. Bacterial growth is shown in yellow colour and the absence of it is 
white. There is a gradient on the concentration of the antibiotic, halving it on each well from left to right. Each line 
represents a different drug. The MIC will be found on the well that shows zero growth but is followed by one with 
bacterial growth. (Emery Pharma) 
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3.3-Quantification of Biofilm Production by Crystal Violet 
Staining 
Biofilm formation was evaluated by means of the crystal violet staining assay as described before 
(Merritt et al; 2005). Bacterial isolates were grown overnight in Mueller-Hinton broth (MHB) at 
37 °C with shaking.  Optical density (OD) of bacterial cultures was measured at 620nm using a 
plate reader (Infinite® 200 PRO, Tecan) and adjusted with MHB to an OD= 0.1.  
Biofilms were developed in 96 well plates. One hundred microliters of the adjusted cultures were 
placed in each well and statically incubated overnight at 37°C. The following day, planktonic 
bacteria were removed, and wells were washed three times with milliQ water. Plates were air 
dried for approximately 20 minutes and then 100μL of a 0.7% crystal violet solution (w/v) were 
added to the wells. After 15 minutes wells were rinsed three times with milliQ water to remove 
excess stain. One hundred microliters of a 33% acetic acid solution (v/v) was added to the wells 
and plates were incubated at room temperature until crystal violet-stained biofilms were 
completely solubilised. The amount of dye (proportional to the density of adherent cells) was 
determined at 620nm. Results were corrected for background staining by subtracting the value 
for crystal violet bound to uninoculated MHB control wells. Normalized biofilms were calculated 
by dividing the total biofilm value (expressed as the OD620) by the bacterial growth for each isolate 
(expressed in CFUs). The biofilm assay was performed three times, with duplicates in each assay. 
 
 
Figure 11: Example of a crystal violet biofilm quantification. The darker the well, the bigger the amount of biofilm 
produced. (Darwish & Asfour; 2013) 
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3.4-Development of Biofilm in Chambers for Confocal 
Microscopy 
To evaluate the shape and viability of the biofilms produced by the different isolates, 13ml tubes 
(Sarstedt, Nümbrecht, Germany) with 3ml of inoculated MHB were grown overnight at 37ºC with 
shaking. The following day, the different isolates were adjusted at the same OD620. 200µl of 
culture were placed into each chamber (Ibidi, Martinsried, Germany). Chambers were then placed 
in the incubator with a certain angle (around 45º), this will allow the biofilm to grow in the middle 
of the chamber, making it easier to find on the microscope. After overnight growth at 37ºC, 
supernatant was removed, and the chambers were rinsed twice with 300µl milliQ water. Live/dead 
staining gets prepared then, by mixing 1.5µl of propidium iodide and 1.5µl of SYTO9 
(ThermoFisher) in 2ml of milliQ water. After 15-30 minutes of staining, the chambers were 
observed through the confocal microscope. 
 
3.5-Bacterial Adhesion and Internalization Assays  
A549 human lung epithelial cells ATCC® CCL-185™ (American Type Culture Collection, 
Manassas, VA) were employed to carry out in parallel adhesion and internalization (invasion) 
experiments. A549 cells were cultured in DMEM/F12 supplemented with 10% foetal bovine 
serum (FBS, ThermoFisher Scientific) at 37°C in an incubator with 5% CO2. Cell suspensions 
were seeded in 24-well standard polystyrene cell culture plates (Sarstedt, Nümbrecht, Germany) 
at 4x105 cells per well, and grown to confluence in the same medium mention above. Cells were 
infected with approximately 4x106 CFU/ml of each P. aeruginosa isolate, suspended in 
DMEM/F12 medium to obtain a multiplicity of infection (MOI) of approximately 10, relative to 
the number of cells initially seeded, and incubated for 1 hour at 37°C with 5% CO2. Strain PAO1 
was used as control at the same concentration. After the incubation period the cells were gently 
washed three times with sterile PBS (1X) to remove non-adherent bacteria. Bacterial suspension 
were recovered and then vortexed for 1 minutes, and 10-fold serial dilutions of each sample were 
carried out followed by plating onto Mueller Hinton agar (MHA) to determine the number of 
CFU/ml which adhered to A549 cells.  
 
For internalization assays, infected cells were extensively washed with sterile PBS after 1 hour of 
incubation at 37°C and further incubated for 45 minutes in DMEM/F12 medium supplemented 
with gentamicin (100 μg/ml) (colistin was used for gentamicin-resistant isolates) in order to 
eliminate extracellular bacteria. After incubation, infected monolayers were washed three times 
with PBS to remove dead bacteria and then lysed with a solution of 1% Triton X-100 (Sigma-
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Aldrich) in PBS for 5 minutes at room temperature. The resultant cell lysates were serially diluted 
and plated onto Mueller Hinton agar plates to quantify viable intracellular bacteria. For 
quantification of extracellular bacteria (adherence assay), we subtracted the number of 
intracellular bacteria (determined by CFUs/ml) obtained after killing extracellular bacteria with 
the corresponding antibiotics (invasion assay) from the total bacteria recovered in the absence of 
antibiotics.  Internalization is calculated as the ratio between the CFUs after the lysis of the A549 
cells and CFUs in the culture supernatant. 
 
3.6-Immunology Assays for Confocal Microscopy 
This experiment was conducted in parallel with adhesion and internalization assays. For this 
experiment, A549 human lung epithelial cells ATCC® CCL-185™ (American Type Culture 
Collection, Manassas, VA) were employed. A549 cells were cultured in DMEM/F12 
supplemented with 10% foetal bovine serum (FBS, ThermoFisher Scientific) at 37°C in an 
incubator with 5% CO2. Cell suspensions were seeded in 24-well standard polystyrene cell 
culture plates (Sarstedt, Nümbrecht, Germany) at 4x105 cells per well, and grown to confluence 
in the same medium mention above. Cells were infected with approximately 4x106 CFU/ml of 
each P. aeruginosa isolate, suspended in DMEM/F12 medium to obtain a multiplicity of infection 
(MOI) of approximately 10, relative to the number of cells initially seeded, and incubated for 1 
hour at 37°C with 5% CO2. After 1h, wells were washed with milliQ water and 3.2% 
paraformaldehyde is applied to fix the sample and stored in the freezer until next step is taken. 
The following day, infected monolayers were lysed with a solution of 1% Triton X-100 (Sigma-
Aldrich) in PBS for 15 minutes at room temperature. After that, unspecific epitopes were blocked 
with 1% BSA in PBS for another 15 minutes. Specific anti-Pseudomonas  rabbit polyclonal 
antibodies 1:1000 on PBS were then applied for 15 minutes again, following this step the sample 
is rinsed carefully with PBS twice and secondary antibody (Alexa goat anti-rabbit) 1:1000 is 
applied for another 15 minutes. Once this step was done and after the sample was cleaned again 
with PBS twice, A488 phalloidin 1:200 is applied for 30 minutes. Finally, the sample is mounted 
with a glue FluoroShield™ (Sigma) that already contains DAPI and it can be carried to the 
microscope. 
 
3.7-DNA Sequencing and Analysis 
Total DNA from the P. aeruginosa isolates was purified by using the DNeasy Blood & Tissue 
Kit (Qiagen) and sequenced on a MiSeq device using reagents kit v3 for 2×300 paired-end 
libraries (Illumina) as previously described. 
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Raw reads from the sequencing platform were directly analyzed by using the in-house 
bioinformatics pipeline TORMES®, using P. aeruginosa PAO1 as reference strain. The options 
used in this study included quality control and filtering of the reads by using Trimmomatic, 
Prinseq and Kraken. Genome assembly was performed with SPAdes and Quast and genome 
annotation with Prokka. Multi-locus sequence typing (MLST). Search of antibiotic resistance 
genes and plasmid replicons was done using BLAST and ABRicate against ResFinder and 
PlasmidFinder databases, respectively, while point mutation investigation in genes known to 
confer antibiotic resistance was performed with PointFinder. Pangenome was created with Roary 
and FastTree. Tormes analysis lasted ~20 hours in a 128 GB RAM 32 cores computer. In silico 

















4.1-Antibiotic susceptibility of clinical isolates 
According to EUCAST breakpoints, MIC range for the isolates were 4 - 128µg/ml for AZT, 1 - 
128+µg/ml for FEP, 0.5 - 128+µg/ml for CAZ, 2 - 256+µg/ml for PIP, 2 - 256+µg/ml for TZP, 
0.5 – 64+µg/ml for IMP, 0.06 – 64+µg/ml for MER, 0.06 – 64+µg/ml for DOR, 0.25 - 64µg/ml 
for AMK 0.25 - 64µg/ml for GEN, 0.06 – 64+µg/ml for TOB, 0.5 – 256+µg/ml for NET, 0.03 – 
32+µg/ml for CIP, 0.125 – 32+µg/ml for LEV, 0.125 – 32+µg/ml for COL, and 4 – 256+µg/ml 
for FOS.   
 
 
Figure 12: % of the 38 isolates non-susceptible to treatment with the different antibiotics. According to EUCAST, non-
susceptible strains are the ones with intermediate or fully resistant profiles against each drug (I + R). 
As we can see in Figure 12, 34.2% of the isolates were non-susceptible Pseudomonas aeruginosa 
(NSPA) for AZT. In cephalosporines, 50% were NSPA for FEP and 44.7% for CAZ. For 
antibiotics inactivating B-lactamases, highest values come from PIP and TZP with 57.9% of 
NSPA isolates. Isolates showed more resistance among carbapenems to IMP and MER with 
73.7% of NSPA isolates followed by DOR. For aminoglycosides, isolates were NSPA in more 
than 40% of the cases, excluding amikacin. Our isolates presented NSPA rates around 50% for 
fluoroquinolones and 70% for FOS. Finally, antibiotics that seemed to be the most efficient were 
AMK and COL with 81.6% of susceptible isolates. 
After evaluating the susceptibility profiles of the different isolates, the collection of 38 was 
grouped according to their resistance profiles. Extremely-drug-resistant (XDR) isolates were 
AZT FEP CAZ PIP TZP IMP MER DOR AMK GEN TOB NET CIP LEV COL FOS
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those NSPA to at least 6 antibiotic categories, multi-drug-resistant (MDR) isolates were NSPA to 
3 – 5 antibiotic categories, moderately resistant (modR) isolates were the ones NSPA to 1 or 2 
antibiotic categories, and finally, multi-susceptible (multiS) isolates were those susceptible to all 
the antibiotic categories. 
 
 
Figure 13: % of the 38 isolates that belong to the 4 previously described resistance profiles. 
 
Results showed that a total of 17 (44.7%) isolates met the extremely-drug-resistant (XDR) 
criteria, 8 (21.1%) were multi-drug-resistant (MDR), 9 (23.7%) were moderately resistant 




















In order to classify biofilm production, the average of the 3 crystal violet measures was then 
divided by the log10 of the CFU of each isolate so that it was normalized. For the interpretation 
of biofilm results, isolates were classified as non-biofilm producer (OD ≤ 0.05), weak-biofilm 




    Figure 14: Biofilm production in the different isolates according to the classification explained above. 
 
Moderate-biofilm producers were the most common among our isolates (34.2%). With 26.3% of 
the isolates each, non-biofilm producers and strong-biofilm producers made up for more than half 



















4.3-Biofilm Development in Chambers 
Biofilm architecture was also evaluated through confocal microscopy. Figure 15 shows biofilms 
produced by different isolates. Green colour represents alive bacterial cells within the biofilm, 
whereas dead cells are shown in red. 
 
 
Figure 15: Biofilm formation under confocal microscope. Upper panel shows three-dimensional structure of the 
biofilms while lower panel shows biofilm in detail. a) PANAVIR 64, b) PANAVIR 117 and c) PANAVIR 180. 
 
As expected, morphology of biofilms was variable. In panel a, PANAVIR 64 represents a weak 
biofilm producer, which correlates with the results observed by the CV method. Most bacteria 
within this biofilm were alive (green colour), and we can see how thin the biofilm is. In panel b, 
PANAVIR 117 shows a robust biofilm morphology. However, most of the bacterial cells within 
the biofilm structure are dead as they present a red colour. When we compare this with its biofilm 
production by the CV method, we can see that it belongs to the moderate-biofilm producer 
category. The biofilm is thicker when compared to PANAVIR 64. In panel c, PANAVIR 180 
shows a high biofilm production where large green masses of bacteria can be seen inside these 
structures, which means that most of the biofilm is composed by alive cells. This isolate was 






4.4-Interaction of P. aeruginosa clinical isolates with A549 
cells 
Percentage of invasion from the different isolates is presented in Table 5 below. Isolate numbers 
in yellow belong to high risk clones, whose percentages of invasion are represented in Figure 16. 
 
Table 5: Invasion percentages of the isolates. Only 33 were analysed due to lack of time, PANAVIR 8, 37, 159, 216 




Figure 16: Invasion percentages of the isolates belonging to high-risk clones. 
 
Strain Invasion % Strain Invasion % Strain Invasion %
PANAVIR 5 0,0 PANAVIR 66 0,0 PANAVIR 173 2,1
PANAVIR 19 0,1 PANAVIR 70 9,7 PANAVIR 175 35,6
PANAVIR 28 1,2 PANAVIR 80 0,9 PANAVIR 178 1,3
PANAVIR 30 7,2 PANAVIR 81 0,8 PANAVIR 180 0,0
PANAVIR 31 0,6 PANAVIR 85 0,2 PANAVIR 185 36,8
PANAVIR 45 0,0 PANAVIR 108 0,0 PANAVIR 187 3,3
PANAVIR 46 25,0 PANAVIR 109 0,0 PANAVIR 195 4,4
PANAVIR 56 0,1 PANAVIR 117 0,0 PANAVIR 196 0,8
PANAVIR 57 56,0 PANAVIR 125 2,1 PANAVIR 206 10,3
PANAVIR 60 0,0 PANAVIR 145 6,8 PANAVIR 211 0,1
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Most of the isolates represented in the figure showed extremely low invasion percentages, 14 out 
of 18 below 10%, this can be explained due to their high cytotoxicity, that, during the 1h infection 
time already killed all the cells. PANAVIR 57 with 56% shows the higher invasion rate followed 
by PANAVIR 64 with 37.9% and PANAVIR 175 with 35.6%. 
In order to see the virulence capacity of the isolates and confirm the data from the invasion 
analysis, cell infection was performed and then seen through the confocal microscope. Cells are 
seen in green colour with the nucleus in blue, bacteria are shown in red. 
 
 
Figure 17: Cell infection through confocal microscope. control) Non-infected cells, a) PANAVIR 19, b) PANAVIR 45 
(VIM20+), c) PANAVIR 70, d) PANAVIR 109 (VIM2+) and e) PANAVIR 175 (GES7+). 
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In Figure 17, when comparing panel a, PANAVIR 19, to the control cells, we can appreciate 
bacteria mostly in the surface of the cells, which remain apparently healthy. This isolate presented 
a very low percentage of invasion (0.1%). Panel b represents isolate PANAVIR 45. Here, it can 
be observed an increased number of bacteria surrounding the cells, whose morphology has 
changed completely, some of them were round-shaped, which indicates cellular damage. In panel 
c, PANAVIR 70, shows a large number of bacteria, mostly around the cells, which still look 
healthy, some bacteria seem to be inside the cells. In panel d, PANAVIR 109, a scarce number of 
bacteria is seen, even though cells look clearly affected, with most of them already round-shaped. 
This isolate presented a very low percentage of infection but appears to exhibit a cytotoxic 
phenotype according to the damage caused to A549 cells.  Finally, in panel e, PANAVIR 175, 
displays a huge amount of bacteria, as well as many cells showing clear signs of apoptosis. This 
isolate presented one if the highest percentages of invasion (35,6%) 
Isolates chosen to be represented on Figure 17 were selected due to their genetic profiles. 
PANAVIR 19 as an example of a non-high-risk clone with low invasion percentage. PANAVIR 
45 as the only isolate with blaVIM-20, PANAVIR 70 as a high-risk clone that seems not to kill the 
cells. PANAVIR 109 as the only isolate with blaVIM-2, and PANAVIR 175 as an isolate that has 
both blaVIM-1 and blaGES-7 (See details in the Resistome results section below). 
 
4.5-Clonal Relatedness and Resistance Profiles of Clinical 
Isolates  
After analyzing the sequencing results given by MLST the 38 isolates were grouped in 19 allelic 
profiles or sequence types (STs). Among these, 19 were considered as high-risk international 
clones (STs: 111, 155, 175 and 235). 
 
Table 6: Number of isolates that belong to the 4 high-risk clones found in our isolates. 









Figure 18: Different resistance profiles seen on high-risk clones found on our isolates. 
 
In Figure 18, focusing only on high-risk clones resistance profiles, results showed that 15 




Figure 19: Different resistance profiles seen on each of the high-risk STs found on our isolates. 
 
Focusing on the resistance profile of each high-risk clone, it was observed that ST155 and ST175 
were the most resistant clones (and the most common) with a 100% and 89% of extremely-drug-
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4.6-Resistome of the 38 VAP P. aeruginosa Isolates 
 
 
Figure 20: Presence of genes which confer resistance to antibiotics from aminoglycoside family found on our isolates. 
 
According to the DNA sequencing performed to the 38 isolates, 9 well known genes responsible 
for aminoglycoside antibiotic resistance were found. aph(3’)-IIb_1 and aph(3’)-IIb_2 were the 
ones with higher presence, 50% and 44.7% respectively. Appearance rates decreased dramatically 
to 21.1% for ant(2’’)-Ia_6 and 15.8% for aac(3)-If_1 & aph(3’)-XV_1. Finally, aadA6_1, aac(3)-
IIa_1, aadA13_1 and aph(6)-I_d were only present in 2 or 1 of the isolates. 
 
 







































Genes for B-lactams Resistance
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In Figure 21, according to the DNA sequencing performed to the 38 samples, 15 well known 
genes responsible for β-lactamase synthesis thus conferring β-lactam resistance were found. 6 of 
them belong to the OXA type being blaOXA-396_1 present in 31.6% of isolates followed by blaOXA-
50_1 found in 28.9% of them. blaPAO_2 with a 42.1% of presence was the most common among the 
15. Two copies of the gen coding for  the extended spectrum betalactamase GES-7 and the 
metallobetalactamase-coding gene blaVIM-1 were found within a class 1 integron in 6 isolates and 
blaVIM-20 in one isolate on an class 1 integron together with other antibiotic resistant determinants 
(Figure 22). 
 
Figure 22: Genetic context of blaGES-7, blaVIM-2 (a) and blaVIM-20 (b). 
 
 
Figure 23: Presence of genes which confer resistance to particular antibiotics used in clinic. 
 
According to the DNA sequencing performed to the 38 samples, other antimicrobial resistance-
related genes were found. catB7_1 is present in most of the isolates (94.7%) giving resistance to 
Chloramphenicol. fosA_4 follows with 92.1%, giving resistance to Fosfomycin. Lastly, crpP_1 

















Twenty important different virulence genes are shown in the figures below, these genes were 
selected in order to cover the different aspects of P. aeruginosa virulence, genes from T3SS, 
T6SS, biofilm or QS are shown. 
 
 
Figure 24: Presence of genes directly related to virulence found on our isolates. a) Genes that belong to the different 
secretion systems (T2, T3 and T6), b) Genes potentially important for biofilm formation, Quorum Sensing, formation 
of flagellum and invasion of cells, and c) Distribution of exoS/exoU genotypes on the 38 isolates. 
 
Panel a: Out of the 4 main effectors from T3SS, exoT and exoY were found on almost all isolates, 
97.4% and 100%, respectively. exoS was present in 57.9% of the isolates while exoU in 28.9%. 
It is known that these two genes are mutually exclusive, but there are some "rare" isolates that 
have both genes (Panel c for more detailed information). When infection and invasion rates of 
isolates with genotypes exoS and exoU were compared, it was possible to detect the difference 
between them. The isolates showing exoS were more invasive (11.2% vs 6.1% on average) but 
less virulent towards cells (40% vs 27% of isolates did not affect the cells), while exoU isolates 
invaded less but their attacks provoked more cellular damage to A549 cells. Genes lasA, lasB and 
toxA were found in all the isolates (100%). T6SS effectors tse1, 2 and 3 were found in most of 
the isolates, 97.4% for tse1 and 94.7% for tse2 and tse3. 
34 
 
Panel b: The 3 genes related with biofilm production (algD, algL and algX) were found on the 38 
isolates studied. Genes rhlC and rhlI related with Quorum Sensing were very common, found in 
100% and 84.2% respectively, while rhlR was only present in 1 isolate. Lipases lipA and lipC 
were also in almost all isolates (100% and 97.4% respectively). fliC gene, which encodes for 
flagellin was present in all isolates while nan1 related to adhesion to other cell types thus allowing 
easier infections was only found on 39.5% of the isolates. 
 
5.- Discussion 
Ventilator-associated pneumonia is one of the most typical infections occurring on the intensive 
care units (ICUs) across the globe as well as one of the major causes of morbidity, mortality, and 
increased funding for ICUs (Joseph et al; 2010). Therefore, it is a critical problem of public health 
that needs to be addressed in a short period of time, as the number of bacteria resistant to 
antibiotics will keep rising (WHO; 2015). P. aeruginosa is a really versatile bacteria, it possesses 
many characteristics that facilitate infection, and it is considered one of the main microorganisms 
causing VAP (Trouillet et al; 1998). For these reasons, this project has focused on describing the 
different characteristics of P. aeruginosa that make it such a problematic pathogen, its virulome 
and resistome as well as phenotypic characteristics and infection models. 
Thanks to whole genome sequencing (WGS) and bioinformatics analysis software we were able 
to identify 19 high-risk clones among our 38 isolates. High-risk clones are specially linked to a 
bad prognosis due to the great amount of antibiotic resistance present in these isolates, most of 
them considered XDR, and their ability to spread (Oliver et al; 2015). Also, we found extended 
spectrum betalactamase GES-7 in and metallobetalactamase VIM-1 in 6 isolates while VIM-2 
and VIM-20 were present in 1 isolate each. The prevalence of these enzymes on Spanish P. 
aeruginosa clinical isolates was similar to other studies such as Bothelo et al; 2019.  
We expected XDR isolates to be less virulent due to a trade-off between pathogenicity and 
antibiotic resistance capability. However, we were able to find highly virulent isolates that also 
presented several antibiotics resistant determinants and display a multi-drug resistant phenotype. 
Out of the 19 high-risk clones, 15 of them were XDR and 3 MDR while presenting at the same 
time a wide number of virulence genes like lasA, lasB, exoA, fliC or lipC. PANAVIR 45, 109 or 
175 are really good examples of this finding, all of them are considered XDR isolates, which are 
also metallobetalactamase VIM-producers (VIM-20, VIM-2 and VIM-1, respectively). Only 1 
high-risk clone presented the multiS phenotype, but remained highly virulent when checked on 
the confocal microscope. We also evaluated the biofilm production, as it is considered an 
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important factor for the development of VAP. 26.3% of the isolates were strong biofilm producers 
(PANAVIR 175 included).  
These results are preliminary, as we only worked with 38 out of more than 200+ isolates from 
Spanish VAP patients, which altogether require a lot of analysis. Due to the pandemic situation 
time was not enough to perform such a thorough evaluation. Further research is needed to better 
correlate pathogenicity and antibiotic resistance, as results like the ones observed in this work 
with PANAVIR 175 can give us an insight on the right direction, possibilities of better 
understanding this relationship on P. aeruginosa can be crucial for clinic. 
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